FDC growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+3.0%+8.5%+8.9%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+6.6%−4.1%+34.9%
+5.8%−9.2%+40.8%
+5.5%−12.5%+57.4%
+5.5%−11.8%+59.3%
+7.6%+10.0%+5.3%
+8.9%+8.8%+5.8%
−36.9%+43.8%+42.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

FDC₹336.00

FDC Limited

· Pharma & Health
₹ CrorePeersIOLCPMOREPENLABINNOVACAPORCHPHARMASENORESGUJTHEMRPGLIFESANOFIMcap ₹5,470 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—+8.9+8.5+3.0—
EBITDA Growth—+34.9-4.1+6.6—
EBIT Growth—+40.8-9.2+5.8—
Net Income Growth—+57.4-12.5+5.5—
EPS Growth—+59.3-11.8+5.5—
Total Assets Growth—+5.3+10.0+7.6—
Total Equity Growth—+5.8+8.8+8.9—
Cash from Operations Growth—+42.5+43.8-36.9—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.